Next-generation histopathologic diagnosis: A lesson from a hepatic carcinosarcoma

Journal of Clinical Oncology

Volumn 32, Issue 17, 2014, Pages

  Luchini, Claudio ^a   Fassan, Matteo ^a   Simbolo, Michele ^a   Mafficini, Andrea ^a   Pedica, Federica ^a   Corbo, Vincenzo ^a   Capelli, Paola ^b   Ruzzenente, Andrea ^b   Guglielmi, Alfredo ^b   Scarpa, Aldo ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3;

AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SIZE; CANCER SURGERY; CARCINOSARCOMA; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DNA SEQUENCE; GENE SEQUENCE; GENOME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CARCINOSARCOMA; LIVER CELL CARCINOMA; LIVER PARENCHYMA; LIVER RESECTION; LOSS OF APPETITE; MALE; ONCOGENE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHABDOMYOSARCOMA; ULTRASOUND; UPPER ABDOMINAL PAIN; WEAKNESS;

AGED; CARCINOSARCOMA; HUMANS; LIVER NEOPLASMS; MALE;

EID: 84902343334     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.47.5855     Document Type: Article

References (18)

1. Bosman FT, Carneiro F, Hruban RH, et al (eds): WHO Classification of Tumours of the Digestive System (ed 4). Lyon, France, International Agency for Research on Cancer, 2010
2. Wang QB, Cui BK, Weng JM, et al: Clinicopathological characteristics and outcome of primary sarcomatoid carcinoma and carcinosarcoma of the liver. J Gastrointest Surg 16:1715-1726, 2012
3. Fayyazi A, Nolte W, Oestmann JW, et al: Carcinosarcoma of the liver. Histopathology 32:385-387, 1998
4. Roncalli M, Terracciano L, Di Tommaso L, et al: Liver precancerous lesions and hepatocellular carcinoma: The histology report. Dig Liver Dis 43:S361-S372, 2011 (suppl 4)
5. Cingolani P, Platts A, Wang le L, et al: A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6:80-92, 2012
6. Thompson L, Chang B, Barsky SH: Monoclonal origins of malignant mixed tumors (carcinosarcomas): Evidence for a divergent histogenesis. Am J Surg Pathol 20:277-285, 1996 (Pubitemid 26071508)
7. Schaefer IM, Schweyer S, Kuhlgatz J: Chromosomal imbalances in primary hepatic carcinosarcoma. Hum Pathol 43:1328-1333, 2012
8. Boyault S, Rickman DS, de Reyniè s A, et al: Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42-52, 2007 (Pubitemid 46144363)
9. Corbo V, Beghelli S, Bersani S, et al: Pancreatic endocrine tumours: Mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Ann Oncol 23:127-134, 2012
10. Barbi S, Cataldo I, De Manzoni G, et al: The analysis of PIK3CA mutations in gastric carcinoma and metanalysis of literature suggest that exon-selectivity is a signature of cancer type. J Exp Clin Cancer Res 29:32, 2010
11. Brooks AN, Kilgour E, Smith PD: Molecular pathways: Fibroblast growth factor signaling-A new therapeutic opportunity in cancer. Clin Cancer Res 18:1855-1862, 2012
12. Byron SA, Gartside M, Powell MA, et al: FGFR2 point mutations in 466 endometrioid endometrial tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 7:e30801, 2012
13. Qiu WH, Zhou BS, Chu PG, et al: Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma. World J Gastroenterol 11:5266-5272, 2005 (Pubitemid 41410290)
14. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 9:669-676, 2003 (Pubitemid 36749215)
15. Glubb DM, Cerri E, Giese A, et al: Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer. Clin Cancer Res 17:5257-5267, 2011
16. Huang J, Zhang X, Tang Q, et al: Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma. J Clin Pathol 64:343-348, 2011
17. Patel SH, Kneuertz PJ, Delgado M, et al: Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma. Ann Surg Oncol 18:3384-3390, 2011
18. Arao T, Ueshima K, Matsumoto K, et al: FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 57:1407-1415, 2013